Sprycel Side Effects

Generic Name: dasatinib

Note: This page contains side effects data for the generic drug dasatinib. It is possible that some of the dosage forms included below may not apply to the brand name Sprycel.

It is possible that some side effects of Sprycel may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to dasatinib: oral tablet

As well as its needed effects, dasatinib (the active ingredient contained in Sprycel) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking dasatinib, check with your doctor immediately:

More common
  • Bloody or black, tarry stools
  • body aches or pain
  • burning, tingling, numbness or pain in the hands, arms, feet, or legs
  • chest pain
  • constipation
  • cough or hoarseness
  • coughing up blood
  • decrease in the amount of urine
  • difficulty with breathing
  • dizziness
  • ear congestion
  • fainting
  • fast, slow, or irregular heartbeat
  • fever or chills
  • full or bloated feeling
  • headache
  • loss of voice
  • lower back or side pain
  • nasal congestion
  • noisy or rattling breathing
  • painful or difficult urination
  • pale skin
  • paralysis
  • pressure in the stomach
  • runny nose
  • sensation of pins and needles
  • severe stomach pain
  • shortness of breath
  • sneezing
  • sore throat
  • stabbing pain
  • swelling of the abdominal or stomach area
  • swelling of the face, fingers, hands, feet, or lower legs
  • tightness in the chest
  • troubled breathing
  • ulcers, sores, or white spots in the mouth
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting of blood or material that looks like coffee grounds
  • weakness in the arms, hands, legs, or feet
  • weight gain
  • wheezing
Less common
  • Bloating
  • blue lips and fingernails
  • chest discomfort
  • coughing that sometimes produces a pink frothy sputum
  • decreased urine output
  • difficult or fast breathing
  • dilated neck veins
  • increased sweating
  • irregular breathing
  • irregular heartbeat
  • nausea
  • swelling
  • swelling in the legs and ankles
Incidence not known
  • Anxiety
  • pain, redness, or swelling in the arm or leg
  • sudden shortness of breath or troubled breathing
  • tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area

Some dasatinib side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common
  • Abdominal or stomach pain
  • bleeding gums
  • cracked lips
  • diarrhea
  • difficulty with moving
  • difficulty with swallowing
  • increased menstrual flow or vaginal bleeding
  • itching skin
  • lack or loss of strength
  • loss of appetite
  • muscle aching or cramping
  • muscle or bone pain
  • muscle stiffness
  • nose bleeds
  • pain
  • pain in the joints
  • prolonged bleeding from cuts
  • red or dark brown urine
  • skin rash
  • swelling or inflammation of the mouth
  • swollen joints
  • vomiting
  • weight loss

For Healthcare Professionals

Applies to dasatinib: oral tablet

Hematologic

In the phase III dose optimization study in patients with chronic phase CML, grade 3 or 4 myelosuppression occurred more frequently in patients treated with the 70 mg twice daily regimen than in those treated with a 100 mg once daily regimen.

Very common (10% or more): Hemorrhage (11 to 26%)
Common (1% to 10%): Febrile neutropenia, pancytopenia
Uncommon (0.1% to 1%): CNS bleeding
Rare (Less than 0.1%): Aplasia pure red cell

General

The most common side effects included fluid retention, musculoskeletal pain, diarrhea, rash, and headache.

Gastrointestinal

Very common (10% or more): Diarrhea (18 to 31%), vomiting (11 to 16%), nausea (18 to 24%), abdominal pain (12%)
Common (1% to 10%): Enterocolitis infection, gastrointestinal bleeding, neutropenic colitis, gastritis, mucositis, stomatitis, dyspepsia, abdominal distension, constipation, oral soft tissue disorder
Uncommon (0.1% to 1%): Pancreatitis, upper gastrointestinal ulcer, esophagitis, ascites, anal fissure, dysphagia
Rare (Less than 0.1%): Protein-losing gastroenteropathy, ileus
Postmarketing reports: Fatal gastrointestinal hemorrhage

Nervous system

Very common (10% or more): Headache (13 to 33%)
Common (1% to 10%): Neuropathy, peripheral neuropathy, dizziness, dysgeusia, somnolence
Uncommon (0.1% to 1%): Syncope, amnesia, tremor
Rare (Less than 0.1%): Cerebrovascular accident, transient ischemic attack, convulsion, optic neuritis, seventh nerve paralysis

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (11 to 22%)
Common (1% to 10%): Arthralgia, myalgia, muscular weakness, musculoskeletal stiffness, muscle spasm, chills
Uncommon (0.1% to 1%): Rhabdomyolysis, muscle inflammation, tendonitis, blood creatine phosphokinase increased

Respiratory

Very common (10% or more): Pleural effusion (11 to 24%), dyspnea (15 to 24%), cough
Common (1% to 10%): Pneumonia (including bacterial, viral, fungal), upper respiratory tract infection, pulmonary edema, pulmonary hypertension, lung infiltration, pneumonitis
Uncommon (0.1% to 1%): Bronchospasm, asthma
Rare (Less than 0.1%): Acute respiratory distress syndrome
Postmarketing reports: Pulmonary embolism, interstitial lung disease, pulmonary arterial hypertension

Metabolic

Common (1% to 10%): Anorexia, appetite disturbances, hyperuricemia, weight decreased, weight increased
Uncommon (0.1% to 1%): Hypoalbuminemia

Hepatic

Uncommon (0.1% to 1%): Hepatitis, cholecystitis, cholestasis

Cardiovascular

Common (1% to 10%): Congestive heart failure, cardiac dysfunction, pericardial effusion, arrhythmia, tachycardia, palpitations, hypertension, chest pain
Uncommon (0.1% to 1%): Myocardial infarction, electrocardiogram QT prolongation, pericarditis, ventricular arrhythmia, ventricular tachycardia, angina pectoris, cardiomegaly, hypotension
Rare (less than 0.1%): Cor pulmonale, myocarditis, acute coronary syndrome
Postmarketing reports: Atrial fibrillation, atrial flutter

Results from phase II single arm clinical studies of 911 patients reported QT prolongation in 9 patients. Three patients (less than 1%) experienced a QTcF greater than 500 milliseconds.

In the phase III dose optimization study in patients with chronic phase CML, pleural effusion and congestive cardiac failure/cardiac dysfunction occurred more frequently in the 70 mg twice a day regimen than in those treated with a 100 mg once daily regimen.

Dermatologic

Very common (10% or more): Skin rash (15 to 21%)
Common (1% to 10%): Flushing, alopecia, dermatitis, eczema, pruritus, acne, dry skin, urticaria, hyperhidrosis, contusion
Uncommon (0.1% to 1%): Acute febrile neutrophilic dermatosis, photosensitivity, pigmentation disorder, panniculitis, skin ulcer, bullous conditions, nail disorder, palmar-plantar erythrodysesthesia syndrome
Rare (Less than 0.1%): Livedo reticularis

Renal

Very common (10% or more): Fluid retention (21 to 42%)
Uncommon (0.1% to 1%): Renal failure, urinary frequency, proteinuria

Other

Very common (10% or more): Fatigue (19 to 26%), superficial edema (10 to 21%), pyrexia (11 to 18%)
Common (1% to 10%): Tinnitus, pain, generalized edema, asthenia
Uncommon (0.1% to 10%): Vertigo, thrombophlebitis, gynecomastia, irregular menstruation, malaise, temperature intolerance
Postmarketing reports: Deep vein thrombosis

Psychiatric

Common (1% to 10%): Depression, insomnia
Uncommon (0.1% to 1%): Anxiety, confusion, affect lability, libido decreased

Hypersensitivity

Uncommon (0.1% to 1%): Erythema nodosum, unspecified hypersensitivity reaction

Ocular

Common (1% to 10%): Visual disturbance, blurred vision, reduction in visual acuity, dry eye
Uncommon (0.1% to 1%): Conjunctivitis
Rare (Less than 0.1%): Visual impairment

Oncologic

Uncommon (0.1% to 1%): Tumor lysis syndrome

Immunologic

Very common (10% or more): Infection (including bacterial, viral, fungal, non-specified) (10 to 14%)
Common (1% to 10%): Sepsis

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)